1. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children
- Author
-
James J. Corbett, Kathleen B. Digre, Deborah I. Friedman, Grant T. Liu, and Michael Wall
- Subjects
Pediatrics ,medicine.medical_specialty ,Hypertension treatment ,Pseudotumor cerebri ,business.industry ,medicine ,Neurology (clinical) ,Pseudotumor cerebri syndrome ,medicine.disease ,business - Abstract
We read with interest the suggestion for new criteria for the diagnosis of pseudotumor cerebri syndrome and idiopathic intracranial hypertension written by our esteemed colleagues.1 We disagree with the need for this exercise since the nomenclature we have used over the years and for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), we believe, is simpler, is accurate, describes the condition, and is easily modified as new information surfaces. Diseases or syndromes should be named for what they are—“idiopathic intracranial hypertension”—rather than what they are not—“pseudotumor cerebri,” “primary pseudotumor cerebri” or “pseudotumor cerebri syndrome (PTCS).” This was impressed on us during a visit to the National Eye Institute many years ago when we were told “we are not going to fund a pseudo anything.” We do not believe there is need for the term PTCS. Secondary causes of intracranial hypertension should also be called what they are: e.g., vitamin A-induced intracranial hypertension, tetracycline-induced intracranial hypertension, steroid withdrawal-related intracranial hypertension, rather than subsuming them with the PTCS acronym. When criteria for IIH are not met and no secondary cause is found, “intracranial hypertension of unknown cause” should …
- Published
- 2014
- Full Text
- View/download PDF